Ultragenyx Pharmaceutical (RARE) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research report sent to investors on Monday. Wedbush currently has a $88.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the company. Morgan Stanley restated an equal weight rating and issued a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Monday, September 10th. Zacks Investment Research raised Ultragenyx Pharmaceutical from a hold rating to a buy rating and set a $86.00 price target on the stock in a report on Wednesday, October 3rd. Credit Suisse Group lowered their price target on Ultragenyx Pharmaceutical from $78.00 to $59.00 and set a hold rating on the stock in a report on Monday, October 29th. JPMorgan Chase & Co. reaffirmed a buy rating and issued a $86.00 price target on shares of Ultragenyx Pharmaceutical in a report on Sunday, October 7th. Finally, Piper Jaffray Companies lowered their price target on Ultragenyx Pharmaceutical to $70.00 and set an overweight rating on the stock in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $73.89.

Shares of NASDAQ RARE opened at $46.79 on Monday. Ultragenyx Pharmaceutical has a 52 week low of $37.44 and a 52 week high of $90.98. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -6.24 and a beta of 2.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) EPS for the quarter, topping the consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The business had revenue of $11.80 million during the quarter, compared to the consensus estimate of $11.97 million. During the same quarter last year, the company earned ($1.87) EPS. The firm’s revenue was up 5800.0% compared to the same quarter last year. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -3.99 earnings per share for the current year.

In related news, Director William Aliski sold 6,000 shares of the firm’s stock in a transaction dated Friday, December 7th. The stock was sold at an average price of $49.69, for a total transaction of $298,140.00. Following the transaction, the director now directly owns 72,610 shares of the company’s stock, valued at approximately $3,607,990.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 8.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in RARE. Capital International Investors raised its holdings in shares of Ultragenyx Pharmaceutical by 20.9% during the 3rd quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock valued at $332,834,000 after buying an additional 755,127 shares in the last quarter. Capital World Investors raised its holdings in shares of Ultragenyx Pharmaceutical by 75.8% during the 3rd quarter. Capital World Investors now owns 1,461,390 shares of the biopharmaceutical company’s stock valued at $111,563,000 after buying an additional 630,088 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 2,221.4% during the 2nd quarter. Voya Investment Management LLC now owns 426,788 shares of the biopharmaceutical company’s stock valued at $32,807,000 after buying an additional 408,403 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Ultragenyx Pharmaceutical by 29.3% during the 3rd quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock valued at $96,453,000 after buying an additional 285,961 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $20,045,000. 97.60% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Story: Purposes and Functions of the Federal Reserve

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply